Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.24 +6.9% TUNG 1.72 +1.8% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.26 −2.6% SGZ 0.045 +0.0% S 0.140 +16.7% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.51 −1.4%
Earnings Routine +

MustGrow Announces First Quarter 2026 Financial Results

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

By The Northwire Desk — AI Analysis May 28, 2026 · 17:01 MGRO · 0.52 MustGrow Biologics Corp.
Executive Summary
  • Q1 2026 Financial Results: TerraSante sales generated $0.1 million in revenue with a gross margin of 23.6%, compared to nil in Q1 2025. Net loss decreased to $1.3 million from $1.6 million in the prior year period.
  • Cash Position: Cash and equivalents totaled $0.4 million as at March 31, 2026, with working capital of $1.5 million.
  • Operational Update: Manufacturing disruptions occurred due to the transition from 'batch' production to 'continuous' lines for TerraSante; capacity expansion is ongoing into Q2 to meet demand.
  • Discontinued Operations: NexusBioAg operations are presented as discontinued operations in this reporting period, though historical data shows it was a key distribution arm previously.
  • Financing Context: A $2 million non-brokered private placement (LIFE Offering) was announced on May 25, 2026, expected to close June 11, 2026, intended to fund inventory and working capital.
Material Impact
  • Revenue Validation: The Q1 revenue of $0.1 million confirms the commercialization start for TerraSante in the U.S., validating the strategic pivot from NexusBioAg Canada to U.S. sales mentioned in 2025 results. However, the absolute value remains small relative to the company's burn rate.
  • Liquidity Risk Mitigation: The cash position of $0.4 million is critically low given a quarterly net loss of $1.3 million and expenses of $0.9 million. This confirms the necessity of the May 25 financing announcement ($2M raise). Since this financing was announced prior to the earnings release, the market has already priced in the capital injection required for survival.
  • Margin Improvement: Gross margin improved to 23.6% from 19.5% in Q1 2025, indicating better pricing or cost control as production scales, though manufacturing disruptions pose a short-term risk to delivery timelines.
  • Net Loss Reduction: The reduction in net loss ($1.6M to $1.3M) is positive but does not indicate profitability; the company remains dependent on external capital for operations.
  • Overall Impact: The news is consistent with previous expectations set by the financing announcement and 2025 full-year results. It confirms operational progress without introducing unexpected negative surprises beyond known liquidity constraints.
MGRO · Price
Company Overview
  • Company: MustGrow Biologics Corp focuses on mustard-derived organic biofertility and biocontrol products.
  • Flagship Product (TerraSante): An organic OMRI-listed wettable powder designed to improve soil microbiome health, nutrient/water use efficiency, and crop yields. It is currently registered in multiple U.S. states including California, Florida, Georgia, Arizona, Idaho, Oregon, Washington, Texas, Utah, and Montana.
  • Secondary Product (TerraMG): A biocontrol product for clubroot disease suppression in canola, with field trials showing up to 95% reduction in spores and yield increases of 7 bushels/acre. Registration is pending with Health Canada.
  • Strategy: Shifted focus from Canadian distribution (NexusBioAg) to U.S. sales growth for TerraSante following the closure of the NexusBioAg Canadian division in April 2026.
Read the original news release →

More from MustGrow Biologics Corp.

Jun 26, 2026 · 17:01

MustGrow Biologics Corp. Announces Results of Shareholder Meeting

Management Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings Jun 17, 2026 · 19:22

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

Financings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other